17,261 trials
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Chronic GVHD Requiring Systemic Immunosuppressive Treatment — 16 percent of patients
Soft Tissue Sarcoma · Fibrous Histiocytoma · Liposarcoma
Primary: Objective Response Rate for Neoadjuvant Bevacizumab Combined With Radiation Therapy for Intermediate and High-risk Soft Tissue Sarcomas. — 2; 4; 3 participants
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: PFS-6 — 1; 8 Participants
Ewing's Sarcoma
Primary: Objective Response Rate of Olaparib — 0 Participants
COPD
Primary: Change From Baseline in Alveolar Macrophage Expression of Nrf2 and Associated Genes at 4 Weeks — 0.80; 1.03; 0.94; 0.90 fold change — p=0.45
Noise-Induced Hearing Loss
Primary: Average Threshold Shift at 4 kHz in Both Ears — 3.94; 3.4; 2.77; 2.03 decibels — p=0.58
Benign Prostatic Hyperplasia
Primary: Change From Baseline at Week 4 in Prostate Specific Antigen (PSA) Concentration. — -0.1; -0.1; -0.3; -0.4 ng/mL — p=0.4678
Nephrogenic Systemic Fibrosis
Primary: Percentage Change From Baseline in the Modified Rodnan Skin Score (mRSS) to Assess Skin Tethering — -24 percentage change in mRSS score
Asthma
Primary: Change in Mean Methacholine Responsiveness as Assessed by the Provocation Concentration Causing a 20% Fall in Forced Expiratory Volume in One Second (FEV1) (PC20) at…
Autistic Disorder
Primary: Total Number of Subjects With Reported Side Effects as Assessed by Dosage Record and Treatment Emergent Symptom Scale (DOTES) — 11; 7; 3; 2 participants
Refractory Plasma Cell Myeloma
Primary: Number of Patients Surviving Progression-free — 14 Participants
Non-Hodgkin Lymphoma · Chronic Lymphocytic Leukemia
Primary: Number of Patients With an Objective Response — 4 Participants
Iris Melanoma · Medium/Large Size Posterior Uveal Melanoma · Ocular Melanoma With Extraocular Extension
Primary: Progression-free Survival (PFS) (Evaluable Randomized Patients) — 7; 15.9 weeks
Food Hypersensitivity
Primary: Percentage of Subjects Who Can Tolerate the Peanut Oral Food Challenge After 12 Months of Peanut SLIT Dosing — 45.5; 0; 11.8; 66.7 percentage of participants
Cocaine Dependence
Primary: Abstinence (Weeks 10 - 11) — 4; 7 Participants